Top Pharma - Others Stocks India (Week of May 10, 2026)

Sector Pulse

The Pharma-Others sub-sector is currently defined by extreme operational divergence. SIGMAADV (formerly Megasoft) has undergone a transformation, reporting a 653% YoY revenue surge to ₹159.41 Cr, primarily fueled by the acquisition of Nasmyth Group. In contrast, UNICHEMLAB is struggling with a 2.24% YoY revenue decline to ₹521.17 Cr, marking its lowest quarterly performance in FY26. While UNICHEMLAB's headline PAT of ₹264.29 Cr appears high, it is entirely artificial, driven by a ₹275.52 Cr exceptional gain from land sales. SIGMAADV, despite its revenue growth, posted a net loss of ₹1.03 Cr due to a 2,145% QoQ spike in employee costs and acquisition-related expenses.

Catalysts Playing Out Across the Pack

Asset monetization and ownership changes are the primary catalysts. SIGMAADV divested its stake in Extrovis AG for $15 million (₹137.61 Cr) and saw its promoter holding double to 71.22%. UNICHEMLAB also utilized asset sales to bolster its cash position. Order book momentum is visible in SIGMAADV, which secured ₹100 Cr in fresh defense-related contracts. However, these catalysts are currently offset by high operational costs and regulatory hurdles.

What Managements Are Guiding

Guidance is sparse and cautious. SIGMAADV management expects a scale-up in FY27 as the Nasmyth acquisition contributes for a full year, targeting margin improvements through synergies. UNICHEMLAB management has provided no quantitative guidance, leaving the market to focus on its 746 bps margin compression and the resolution of regulatory observations.

Sub-Sector Aggregates

EBITDA margins for the analyzed constituents range from 8.59% to 12.5%. The sector is heavily impacted by exceptional items, with one-time impacts ranging from a ₹9.13 Cr cost at SIGMAADV to a ₹275.52 Cr gain at UNICHEMLAB. Regulatory scrutiny is persistent, with both constituents reporting observations or fines from authorities like the USFDA and BSE/NSE.

Shared Risks (9-type taxonomy)

Regulatory and litigation risks are the most prominent. UNICHEMLAB is dealing with five USFDA observations at its Kolhapur facility and has settled a ₹175 Cr (€19.49 million) fine with the European Commission. SIGMAADV faces regulatory risk in the form of exchange fines for board composition. Labor risk is also evident at SIGMAADV, where employee costs reached ₹56.36 Cr, severely impacting the bottom line.

Bottom Line

The sub-sector is in a state of flux, with inorganic growth masking underlying cost pressures and regulatory challenges. While SIGMAADV shows promise through its order book and expansion, UNICHEMLAB's core operational decline and litigation history warrant a cautious approach. Investors should look past headline PAT figures, which are currently distorted by one-time asset sales and acquisition costs.